Trial Profile

A Randomized, Double-blind, Placebo-controlled Phase III Study Evaluating the Efficacy and Safety of IBI362 in Chinese Participants with Obesity or Overweight (GLORY-1)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 11 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 May 2025 Results presented in the Innovent Biologics Media Release.
26 May 2025 According to an Innovent Biologics media release, results from this study have been published in The New England Journal of Medicine (NEJM) with a related editorial. The first authors of this paper are Professor Linong Ji from Peking University People's Hospital and Professor Jiang Hongwei from the First Affiliated Hospital of Henan University of Science and Technology.
02 Sep 2024 According to an Innovent Biologics Media Release, data from this study will be presented at the European Association for the Study of Diabetes (EASD) 60th Annual Meeting in Madrid, Spain from September 9 -13, 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com